SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Peter Singleton who wrote (4803)7/7/1998 1:10:00 PM
From: billkirn  Read Replies (1) of 6136
 
Peter: Maybe a little wishful thinking, but maybe IMNR was going to make broader claims from the Remune trials, however, the Legal Beagles needed to maintain restraint to protect against stockholder suits and FDA *&^%$#. Check the Vical thread for this discussion. Also there may be a greater need for Agouron to be careful since they have an approved drug, while IMNR could have made broader claims without the threat of the FDA concerns. Remember when the FDA scolded Agouron just after approval, seems like there are different news release rules post FDA approval.

Bill
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News